Orphan drug designation granted to voreloxin for acute myeloid leukemia (AML)
Sunesis Pharmaceuticals was granted orphan drug designation by the FDA for its drug candidate, voreloxin for the treatment of acute myeloid leukemia (AML).
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.